Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease is characterized by amyloid-beta plaques, neurofibrillary tangles, gliosis, and neuronal loss. Solanezumab, a humanized monoclonal antibody, preferentially binds soluble forms of amyloid and in preclinical studies promoted its clearance from the brain. METHODS: In two phase 3, double-blind trials (EXPEDITION 1 and EXPEDITION 2), we randomly assigned 1012 and 1040 patients, respectively, with mild-to-moderate Alzheimer's disease to receive placebo or solanezumab (administered intravenously at a dose of 400 mg) every 4 weeks for 18 months. The primary outcomes were the changes from baseline to week 80 in scores on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog11; range, 0 to 70, with higher scores indicating greater cognitive impairment) and the Alzheimer's Disease Cooperative Study-Activities of Daily Living scale (ADCS-ADL; range, 0 to 78, with lower scores indicating worse functioning). After analysis of data from EXPEDITION 1, the primary outcome for EXPEDITION 2 was revised to the change in scores on the 14-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog14; range, 0 to 90, with higher scores indicating greater impairment), in patients with mild Alzheimer's disease. RESULTS: Neither study showed significant improvement in the primary outcomes. The modeled difference between groups (solanezumab group minus placebo group) in the change from baseline was -0.8 points for the ADAS-cog11 score (95% confidence interval [CI], -2.1 to 0.5; P=0.24) and -0.4 points for the ADCS-ADL score (95% CI, -2.3 to 1.4; P=0.64) in EXPEDITION 1 and -1.3 points (95% CI, -2.5 to 0.3; P=0.06) and 1.6 points (95% CI, -0.2 to 3.3; P=0.08), respectively, in EXPEDITION 2. Between-group differences in the changes in the ADAS-cog14 score were -1.7 points in patients with mild Alzheimer's disease (95% CI, -3.5 to 0.1; P=0.06) and -1.5 in patients with moderate Alzheimer's disease (95% CI, -4.1 to 1.1; P=0.26). In the combined safety data set, the incidence of amyloid-related imaging abnormalities with edema or hemorrhage was 0.9% with solanezumab and 0.4% with placebo for edema (P=0.27) and 4.9% and 5.6%, respectively, for hemorrhage (P=0.49). CONCLUSIONS: Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability. (Funded by Eli Lilly; EXPEDITION 1 and 2 ClinicalTrials.gov numbers, NCT00905372 and NCT00904683.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Florbetapir PET analysis did not show a reduction in brain amyloid deposits with solanezumab [45, 46].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [45]
In the citing paper
“bapineuzumab and solanezumab showed no cognitive improvement in Phase 3 trials [46,47]”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [46]
In the citing paper
“Clinical trials often fail to deliver benefits.”
From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [46]
In the citing paper
“and a similar proportion has normal amyloid PET or CSF Aβ42 studies [53–62].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [57]
In the citing paper
“While recent clinical trials of anti‐amyloid therapies, such as donanemab and lecanemab, 2 , 3 have shown promising results, the failures of earlier treatments like solanezumab and bapineuzumab indicate that targeting a single AD‐specific pathological process is insufficient to mitigate cognitive decline. 4 , 5 , 6”
From White matter hyperintensity modulates the amyloid‐tau‐cognition association and anti‐amyloid treatment efficacy in asymptomatic older adults (2025) · cites this paper as [6]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
Sheikh (1986) · doi:10.1300/j018v05n01_09 · Cited by 7,236
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Assessing Quality of Life in Older Adults With Cognitive Impairment
Logsdon, R. G., Gibbons, L. E., McCurry, S. M., & Teri, L. (2002) · Psychosomatic Medicine · doi:10.1097/00006842-200205000-00016 · Cited by 1,381
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Self-citationAn Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease
Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00005 · Cited by 1,194
Self-citationO’Bryant, S. E. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1091 · Cited by 884
Research works printed but not linked: 2
- Wimo A, Wetterholm AL, Mastey V, Winbald B. Evaluations of resource utilization and caregiver time in anti-dementia drug trials- a quantitative battery. In: Wimo A, Jonsson B, Karlsson G, Winbald B, eds. The health economics of dementia. London: John Wiley, 1998:465-99.
- Kind P. 1996. The EuroQol instrument: an index of health-related quality of life. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996:191-201.
Cited by
Items 201–300 of 1,006
Moya-Alvarado, G., Gershoni-Emek, N., Perlson, E., & Bronfman, F. C. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r115.053330 · Cited by 117
Lopez Lopez, C., Tariot, P. N., Caputo, A., Langbaum, J. B., Liu, F., Riviere, M., Langlois, C., Rouzade‐Dominguez, M., Zalesak, M., Hendrix, S., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.02.005 · Cited by 116
Self-citationDeters, K. D., Napolioni, V., Sperling, R. A., Greicius, M. D., Mayeux, R., Hohman, T., & Mormino, E. C. (2021) · Neurology · doi:10.1212/wnl.0000000000011599 · Cited by 115
“The overall goal of this clinical trial is to understand whether intervention with an anti–amyloid antibody treatment (solanezumab) in amyloid+ CN individuals will slow cognitive decline.(21) Participants age 65–85 were assessed to be CN and had scores of 25–30 on the MiniMental State Examination (MMSE), 0 on the glob…”
BackgroundMonteiro, C., Tóth, B. I., Brunstein, F., Bobbala, A., Datta, S., Ceniceros, R., Bohorquez, S. M. S., Anania, V. G., Wildsmith, K. R., Schauer, S. P., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207663 · Cited by 124
Neumann, U., Rueeger, H., Machauer, R., Veenstra, S. J., Lueoend, R. M., Tintelnot-Blomley, M., Laue, G., Beltz, K., Vogg, B., Schmid, P., et al. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0033-8 · Cited by 113
Rembach, A., Watt, A. D., Wilson, W. J., Rainey‐Smith, S. R., Ellis, K. A., Rowe, C. C., Villemagne, V. L., Macaulay, S. L., Bush, A. I., Martins, R. N., et al. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.05.005 · Cited by 121
Sevigny, J., Suhy, J., Chiao, P., Chen, T., Klein, G., Purcell, D., Oh, J., Verma, A., Sampat, M., & Barakos, J. (2016) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000144 · Cited by 114
The neuritic plaque facilitates pathological conversion of tau in an Alzheimer’s disease mouse model
Li, T., Braunstein, K. E., Zhang, J., Lau, A., Sibener, L., Deeble, C., & Wong, P. C. (2016) · Nature Communications · doi:10.1038/ncomms12082 · Cited by 114
The need to show minimum clinically important differences in Alzheimer's disease trials
Liu, K. Y., Schneider, L. S., & Howard, R. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00197-8 · Cited by 113
ACAT1/SOAT1 as a Therapeutic Target for Alzheimer's Disease
Shibuya, Y., Chang, C. C., & Chang, T.-Y. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.161 · Cited by 113
Doniger, G. M., Beeri, M. S., Bahar‐Fuchs, A., Gottlieb, A., Tkachov, A., Kenan, H., Livny, A., Bahat, Y., Sharon, H., Ben‐Gal, O., et al. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.02.005 · Cited by 112
Staging of Alzheimer's disease: past, present, and future perspectives
Therriault, J., Zimmer, E. R., Benedet, A. L., Pascoal, T. A., Gauthier, S., & Rosa-Neto, P. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.05.008 · Cited by 113
ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease
Honig, L. S., Barakos, J., Dhadda, S., Kanekiyo, M., Reyderman, L., Irizarry, M., Kramer, L. D., Swanson, C. J., & Sabbagh, M. (2023) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12377 · Cited by 112
Timmers, M., Streffer, J. R., Russu, A., Tominaga, Y., Shimizu, H., Shiraishi, A., Tatikola, K., Smekens, P., Börjesson-Hanson, A., Andreasen, N., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0415-6 · Cited by 112
“These researchers showed that rates of neuronal injury, cognitive and functional decline, and temporal lobe atrophy substantially accelerated at conventional prethreshold levels for amyloid positivity and may have contributed to lack of efficacy in late-phase clinical trials of antiamyloid therapies [20, 21].”
BackgroundImmunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice
Kastanenka, K. V., Bussiere, T., Shakerdge, N., Qian, F., Weinreb, P. H., Rhodes, K., & Bacskai, B. J. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.2080-16.2016 · Cited by 110
Lacosta, A.-M., Pascual-Lucas, M., Pesini, P., Casabona, D., Pérez-Grijalba, V., Marcos-Campos, I., Sarasa, L., Canudas, J., Badi, H., Monleón, I., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0340-8 · Cited by 111
Wallin, A., Nordlund, A., Jonsson, M. A. G., Lind, K., Edman, Å., Göthlin, M., Stålhammar, J., Eckerström, M., Kern, S., Börjesson‐Hanson, A., et al. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.147 · Cited by 123
Grundman, M., Morgan, R., Lickliter, J. D., Schneider, L. S., DeKosky, S., Izzo, N. J., Guttendorf, R., Higgin, M., Pribyl, J., Mozzoni, K., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.11.001 · Cited by 96
Rezai, A. R., Ranjan, M., Haut, M. W., Carpenter, J., D’Haese, P.-F., Mehta, R. I., Najib, U., Wang, P., Claassen, D. O., Chazen, J. L., et al. (2023) · Journal of Neurosurgery · doi:10.3171/2022.9.jns221565 · Cited by 111
Precision pharmacology for Alzheimer’s disease
Hampel, H., Vergallo, A., Aguilar, L. F., Benda, N., Broich, K., Cuello, A. C., Cummings, J., Dubois, B., Federoff, H. J., Fiandaca, M., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.02.014 · Cited by 108
Bateman, R. J., Cummings, J., Schobel, S., Salloway, S., Vellas, B., Boada, M., Black, S. E., Blennow, K., Fontoura, P., Klein, G., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01110-8 · Cited by 109
Self-citationSlowing the progression of Alzheimer’s disease; what works?
Nelson, L., & Tabet, N. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.07.002 · Cited by 109
Longitudinal brain structural changes in preclinical Alzheimer's disease
Pegueroles, J., Vilaplana, E., Montal, V., Sampedro, F., Alcolea, D., Carmona‐Iragui, M., Clarimon, J., Blesa, R., Lleó, A., Fortea, J., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.010 · Cited by 109
“The unexpected finding of cortical atrophy (without clinical deterioration) seen in previous active (AN1792 trial) [46] and passive (solanezumab [47] and bapineuzumab [48]) immunization trials is better explained if we consider the pathologic thickening associated with brain amyloidosis [11].”
BackgroundAlzheimer's drug‐development pipeline: 2016
Cummings, J., Morstorf, T., & Lee, G. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.07.001 · Cited by 108
“Monoclonal antibody approaches have instituted two major changes in drug development based on experiences with the failure of bapineuzumab: (1) patient populations with more mild disease are now the focus of trials [12]; (2) amyloid imaging or CSFAb measures are performed at baseline to insure that patients have the t…”
BackgroundAlzheimer’s Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid
Huynh, R. A., & Mohan, C. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00102 · Cited by 108
“org March 2017 | Volume 8 | Article 102 trials, where they ultimately failed (115, 116, 120, 121).”
BackgroundPan, R.-Y., Zhang, J., Wang, J., Wang, Y., Li, Z., Liao, Y., Liao, Y., Zhang, C., Liu, Z., Song, L., et al. (2022) · Nature Aging · doi:10.1038/s43587-022-00311-y · Cited by 107
Zhu, K., Xiang, X., Filser, S., Marinković, P., Dorostkar, M. M., Crux, S., Neumann, U., Shimshek, D. R., Rammes, G., Haass, C., et al. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.12.023 · Cited by 107
Stem Cell Therapy for Alzheimer’s Disease: A Review of Recent Clinical Trials
Kang, J. M., Yeon, B. K., Cho, S., & Suh, Y. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160406 · Cited by 111
Cimenser, A., Hempel, E., Travers, T., Strozewski, N., Martin, K., Malchano, Z., & Hajós, M. (2021) · Frontiers in Systems Neuroscience · doi:10.3389/fnsys.2021.746859 · Cited by 107
Fišar, Z. (2022) · Biomolecules · doi:10.3390/biom12111676 · Cited by 120
“Disease-modifying drugs are also the monoclonal antibodies directed at Aβ; besides aducanumab [374] it is also gantenerumab [374,375], lecanemab [375], donanemab [376], and solanezumab [374,377], which have shown some efficiency and are tested in phase 3 clinical trials [317].”
BackgroundViayna, E., Coquelle, N., Cieslikiewicz-Bouet, M., Cisternas, P., Oliva, C. A., Sánchez-López, E., Ettcheto, M., Bartolini, M., De Simone, A., Ricchini, M., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01775 · Cited by 106
Anti‐amyloid antibody treatments for Alzheimer's disease
Perneczky, R., Dom, G., Chan, A., Falkai, P., & Bassetti, C. (2024) · European Journal of Neurology · doi:10.1111/ene.16049 · Cited by 106
“The first anti-A β antibody to be studied in phase 3 Clinical trials of solanezumab have yielded mixed results, with some studies showing a slowing of cognitive decline in mild AD patients whilst others did not show significant benefits [13].”
ResultLi, X., Wang, X., Su, L., Hu, X., & Han, Y. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-028188 · Cited by 106
“(4) Other diseases that could cause cognitive decline (eg, thyroid dysfunction, severe anaemia, syphilis, or HIV).”
BackgroundTse, K., & Herrup, K. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14079 · Cited by 105
Innes, K. E., Selfe, T. K., Brundage, K., Montgomery, C., Wen, S., Kandati, S., Bowles, H., Khalsa, D. S., & Huysmans, Z. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180164 · Cited by 105
Zeltins, A., West, J., Zabel, F., El Turabi, A., Balke, I., Haas, S., Maudrich, M., Storni, F., Engeroff, P., Jennings, G. T., et al. (2017) · npj Vaccines · doi:10.1038/s41541-017-0030-8 · Cited by 104
“Frames from each movie were aligned and averaged to produce drift-corrected micrographs.(27) Data are summarized in Table S1.”
Folch, J., Ettcheto, M., Petrov, D., Abad, S., Pedrós, I., Marin, M., Olloquequi, J., & Camins, A. (2018) · Neurología (English Edition) · doi:10.1016/j.nrleng.2015.03.019 · Cited by 101
A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia
Wang, T., Kuang, W., Chen, W., Xu, W., Zhang, L., Li, Y., Li, H., Peng, Y., Chen, Y., Wang, B., et al. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00678-3 · Cited by 103
Doré, V., Bullich, S., Rowe, C. C., Bourgeat, P., Konate, S., Sabri, O., Stephens, A. W., Barthel, H., Fripp, J., Masters, C. L., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.02.005 · Cited by 93
Pasquier, F., Sadowsky, C., Holstein, A., Leterme, G. L. P., Peng, Y., Jackson, N., Fox, N. C., Ketter, N., Liu, E., Ryan, J. M., et al. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150376 · Cited by 102
(2020) · Brain · doi:10.1093/brain/awaa403 · Cited by 103
“A key possible reason for the negative results seen in many of the earlier amyloid-lowering therapy trials was lack of biomarker evidence of Alzheimer’s disease in the full recruited study populations (Doody et al., 2014; Salloway et al., 2014; Vandenberghe et al., 2016).”
ResultAnti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis
Fedele, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914499 · Cited by 102
“Phase III, randomised, double-blind, placebo-controlled (EXPEDITION 1, 2) 80 weeks [54] Mild to moderate AD ADAS-Cog11 and ADCS-ADL Significant small effects for ADCS-ADL only in EXPEDITION 2 Significant small effects in a secondary analysis on the pooled mild AD-population [55] Significant increase in plasma and CSF…”
BackgroundMethodLeoutsakos, J.-M. S., Yan, H., Anderson, W. S., Asaad, W. F., Baltuch, G., Burke, A., Chakravarty, M. M., Drake, K. E., Foote, K. D., Fosdick, L., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180121 · Cited by 104
Alzheimer’s Disease: Mechanism and Approach to Cell Therapy
Amemori, T., Jendelova, P., Ruzicka, J., Urdzikova, L., & Sykova, E. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161125961 · Cited by 102
Revolutionizing Alzheimer's disease and clinical trials through biomarkers
Mattsson, N., Carrillo, M. C., Dean, R. A., Devous, M. D., Nikolcheva, T., Pesini, P., Salter, H., Potter, W. Z., Sperling, R. S., Bateman, R. J., et al. (2015) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.09.001 · Cited by 102
Hao, L., Wang, X., Zhang, L., Xing, Y., Guo, Q., Hu, X., Mu, B., Chen, Y., Chen, G., Cao, J., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170347 · Cited by 108
“However, current treatment studies with new drugs against amyloid- and tau pathology at the mild or moderate dementia stage of the illness have failed [2, 3], suggesting that treatment needs to be applied as early as the preclinical stage of the disease [4].”
The Proteasome and Oxidative Stress in Alzheimer's Disease
Bonet-Costa, V., Pomatto, L. C.-D., & Davies, K. J. A. (2016) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6802 · Cited by 99
Plog, B. A., Mestre, H., Olveda, G. E., Sweeney, A. M., Kenney, H. M., Cove, A., Dholakia, K. Y., Tithof, J., Nevins, T. D., Lundgaard, I., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120922 · Cited by 101
“than the concentration needed to achieve adequate binding of the target antigen in peripheral tissues (1, 17), and these high doses in clinical trials increase the prevalence of adverse events (1, 9, 18) such as amyloid-related imaging abnormalities (ARIA) (19, 20).”
Sun, L., Cho, H.-J., Sen, S., Arango, A. S., Huynh, T. T., Huang, Y., Bandara, N., Rogers, B. E., Tajkhorshid, E., & Mirica, L. M. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c05470 · Cited by 98
Neuropathologic differences by race from the National Alzheimer's Coordinating Center
Graff‐Radford, N. R., Besser, L. M., Crook, J. E., Kukull, W. A., & Dickson, D. W. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.004 · Cited by 100
Treating Alzheimer's disease by targeting iron
Nikseresht, S., Bush, A. I., & Ayton, S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14567 · Cited by 98
“In two Phase 3 trials, solanezumab had no overall benefit to cognition; however, secondary analysis of a subgroup of mild AD patients that were pooled from both trials revealed a slowing of decline associated with treatment (Doody et al., 2014).”
BackgroundAn overview on recent in vivo biological application of cerium oxide nanoparticles
Inbaraj, B. S., & Chen, B. (2019) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2019.10.005 · Cited by 114
“[37] Doody RS , Thomas RG , Farlow M , Iwatsubo T , Vellas B , Joffe S , et al.”
BackgroundEbell, M. H., Barry, H. C., Baduni, K., & Grasso, G. (2024) · The Annals of Family Medicine · doi:10.1370/afm.3050 · Cited by 100
Plaque-associated local toxicity increases over the clinical course of Alzheimer disease
Serrano-Pozo, A., Betensky, R. A., Frosch, M. P., & Hyman, B. T. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.10.010 · Cited by 100
Clearance of Amyloid-Beta in Alzheimer’s Disease: Shifting the Action Site from Center to Periphery
Liu, Y.-H., Wang, Y.-R., Xiang, Y., Zhou, H.-D., Giunta, B., Mañucat-Tan, N. B., Tan, J., Zhou, X.-F., & Wang, Y.-J. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-8694-9 · Cited by 99
Lacorte, E., Ancidoni, A., Zaccaria, V., Remoli, G., Tariciotti, L., Bellomo, G., Sciancalepore, F., Corbo, M., Lombardo, F. L., Bacigalupo, I., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220046 · Cited by 111
Amyloid-Related Imaging Abnormalities: An Update
Roytman, M., Mashriqi, F., Al-Tawil, K., Schulz, P. E., Zaharchuk, G., Benzinger, T. L. S., & Franceschi, A. M. (2023) · American Journal of Roentgenology · doi:10.2214/ajr.22.28461 · Cited by 99
Yang, H., Li, X., Zhu, L., Wu, X., Zhang, S., Huang, F., Feng, X., & Shi, L. (2019) · Advanced Science · doi:10.1002/advs.201901844 · Cited by 98
Kobayashi, E., Nakano, M., Kubota, K., Himuro, N., Mizoguchi, S., Chikenji, T., Otani, M., Mizue, Y., Nagaishi, K., & Fujimiya, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-19442-7 · Cited by 98
Sex differences in Alzheimer’s disease: Understanding the molecular impact
Toro, C. A., Zhang, L., Cao, J., & Cai, D. (2019) · Brain Research · doi:10.1016/j.brainres.2019.05.031 · Cited by 98
Karakatsani, M. E., Kugelman, T., Ji, R., Murillo, M., Wang, S., Niimi, Y., Small, S. A., Duff, K. E., & Konofagou, E. E. (2019) · Theranostics · doi:10.7150/thno.28717 · Cited by 98
“Clinically, several phase III trials have been performed in patients with mild-to-moderate Alzheimer’s disease but failed to show significant improvement in their primary outcomes [10,11].”
BackgroundImmunotherapy for Parkinson’s disease
Schwab, A. D., Thurston, M. J., Machhi, J., Olson, K. E., Namminga, K. L., Gendelman, H. E., & Mosley, R. L. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104760 · Cited by 109
Evaluation of a Genetic Risk Score to Improve Risk Prediction for Alzheimer’s Disease
Chouraki, V., for the International Genomics of Alzheimer’s Project, Reitz, C., Maury, F., Bis, J. C., Bellenguez, C., Yu, L., Jakobsdottir, J., Mukherjee, S., Adams, H. H., et al. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-150749 · Cited by 98
Folch, J., Ettcheto, M., Petrov, D., Abad, S., Pedrós, I., Marin, M., Olloquequi, J., & Camins, A. (2018) · Neurología · doi:10.1016/j.nrl.2015.03.012 · Cited by 97
Jacobsen, H., Ozmen, L., Caruso, A., Narquizian, R., Hilpert, H., Jacobsen, B., Terwel, D., Tanghe, A., & Bohrmann, B. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.1405-14.2014 · Cited by 97
Oral Delivery of Protein Drugs Bioencapsulated in Plant Cells
Kwon, K., & Daniell, H. (2016) · Molecular Therapy · doi:10.1038/mt.2016.115 · Cited by 102
Cogswell, P. M., Andrews, T. J., Barakos, J. A., Barkhof, F., Bash, S., Benayoun, M. D., Chiang, G. C., Franceschi, A. M., Jack, C. R., Pillai, J. J., et al. (2025) · American Journal of Neuroradiology · doi:10.3174/ajnr.a8469 · Cited by 93
Boada, M., Anaya, F., Ortiz, P., Olazarán, J., Shua-Haim, J. R., Obisesan, T. O., Hernández, I., Muñoz, J., Buendia, M., Alegret, M., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160565 · Cited by 94
“Only symptomatic therapies are available for the treatment of AD, and disease-modifying compounds are currently being tested, especially medications that target A metabolism [4, 5].”
BackgroundMolecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies
Crespi, G. A. N., Hermans, S. J., Parker, M. W., & Miles, L. A. (2015) · Scientific Reports · doi:10.1038/srep09649 · Cited by 96
Genetic variants in Alzheimer disease — molecular and brain network approaches
Gaiteri, C., Mostafavi, S., Honey, C. J., De Jager, P. L., & Bennett, D. A. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.84 · Cited by 96
Eyetracking Metrics in Young Onset Alzheimer’s Disease: A Window into Cognitive Visual Functions
Pavisic, I. M., Firth, N. C., Parsons, S., Rego, D. M., Shakespeare, T. J., Yong, K. X. X., Slattery, C. F., Paterson, R. W., Foulkes, A. J. M., Macpherson, K., et al. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00377 · Cited by 96
“org August 2017 | Volume 8 | Article 377 disease-modifying treatments available for AD (6, 7).”
BackgroundDetecting earlier stages of amyloid deposition using PET in cognitively normal elderly adults
Guo, T., Landau, S. M., Jagust, W. J., & Initiative, F. T. A. D. N. (2020) · Neurology · doi:10.1212/wnl.0000000000009216 · Cited by 95
Advances in Alzheimer’s Disease Drug Development
Rafii, M. S., & Aisen, P. S. (2015) · BMC Medicine · doi:10.1186/s12916-015-0297-4 · Cited by 94
Self-citationPanegyres, P. K., Berry, R., & Burchell, J. T. (2016) · Diagnostics · doi:10.3390/diagnostics6010006 · Cited by 99
Wattmo, C., Blennow, K., & Hansson, O. (2020) · BMC Neurology · doi:10.1186/s12883-019-1591-0 · Cited by 93
Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward
Hsu, D., & Marshall, G. A. (2017) · Current Alzheimer Research · doi:10.2174/1567205013666160930112125 · Cited by 93
“Testing drugs in those with already moderate AD dementia was unsuccessful, but there remains a glimmer of hope with testing interventions in those with mild AD dementia or MCI due to AD, given the secondary analyses results of cognitive improvement in the mild AD dementia group alone in the solanezumab, amyloid passiv…”
ResultEFAD transgenic mice as a human APOE relevant preclinical model of Alzheimerʼns disease
Tai, L. M., Balu, D., Avila-Munoz, E., Abdullah, L., Thomas, R., Collins, N., Valencia-Olvera, A. C., & LaDu, M. J. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r076315 · Cited by 93
Self-citationNew fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer’s disease
Park, S. A., Han, S. M., & Kim, C. E. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0418-9 · Cited by 91
Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets
Kwon, S., Iba, M., Kim, C., & Masliah, E. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00853-2 · Cited by 93
MIND Diet, Common Brain Pathologies, and Cognition in Community-Dwelling Older Adults
Dhana, K., James, B. D., Agarwal, P., Aggarwal, N. T., Cherian, L. J., Leurgans, S. E., Barnes, L. L., Bennett, D. A., & Schneider, J. A. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-210107 · Cited by 93
“Identifying modifiable lifestyle factors that act independently of brain pathologies is critical in Alzheimer’s research, in part, because pharmacological interventions that focus on brain pathology have failed to reduce or slow cognitive decline [15], despite some evidence of clearance of amyloid plaque from the brai…”
Resveratrol and Alzheimer’s disease: message in a bottle on red wine and cognition
Granzotto, A., & Zatta, P. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00095 · Cited by 93
Boada, M., López, O., Núñez, L., Szczepiorkowski, Z. M., Torres, M., Grifols, C., & Páez, A. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.01.001 · Cited by 91
CAP—advancing the evaluation of preclinical Alzheimer disease treatments
Reiman, E. M., Langbaum, J. B., Tariot, P. N., Lopera, F., Bateman, R. J., Morris, J. C., Sperling, R. A., Aisen, P. S., Roses, A. D., Welsh-Bohmer, K. A., et al. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.177 · Cited by 91
Self-citationAmyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta pores.
Arbor, S., LaFontaine, M., & Cumbay, M. G. (2016) · PubMed Central · Cited by 135
Cebers, G., Alexander, R. C., Haeberlein, S. B., Han, D., Goldwater, R., Ereshefsky, L., Olsson, T., Ye, N., Rosen, L., Russell, M., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160701 · Cited by 91
“The original, Phase III studies (EXPEDITION 1 & 2) of solanezumab, in patients with mild to moderate Alzheimer’s disease, did not reach their primary endpoint [41].”
ErbB2 regulates autophagic flux to modulate the proteostasis of APP-CTFs in Alzheimer’s disease
Wang, B.-J., Her, G. M., Hu, M.-K., Chen, Y.-W., Tung, Y.-T., Wu, P.-Y., Hsu, W.-M., Lee, H., Jin, L.-W., Hwang, S.-P. L., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618804114 · Cited by 91
Mo, J., Li, J., Yang, Z., Liu, Z., & Feng, J. (2017) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.469 · Cited by 90
“Doody et al.(35) showed no significant improvement in the primary outcomes between solanezumab and placebo group.”
BackgroundInfluentialEcheverria, V., Yarkov, A., & Aliev, G. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.002 · Cited by 91
Dai, C., Chen, X., Kazim, S. F., Liu, F., Gong, C., Grundke, I., & Iqbal, K. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1315-y · Cited by 97
Microbiota-gut-brain axis and toll-like receptors in Alzheimer’s disease
Lin, C., Zhao, S., Zhu, Y., Fan, Z., Wang, J., Zhang, B., & Chen, Y. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.09.008 · Cited by 89
Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse
Lei, P., Ayton, S., Appukuttan, A. T., Volitakis, I., Adlard, P. A., Finkelstein, D. I., & Bush, A. I. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.03.015 · Cited by 93
Yao, L., Gu, X. Q., Song, Q., Wang, X., Huang, M., Meng, H., Hou, L., Kang, T., Chen, J., Chen, H., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.055 · Cited by 93
How early can we diagnose Alzheimer disease (and is it sufficient)?: The 2017 Wartenberg lecture
Petersen, R. C. (2018) · Neurology · doi:10.1212/wnl.0000000000006088 · Cited by 89
The informed road map to prevention of Alzheimer Disease: a call to arms
McDade, E., Llibre-Guerra, J. J., Holtzman, D. M., Morris, J. C., & Bateman, R. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00467-y · Cited by 89
“Despite the scientific strength of the amyloid hypothesis, to date clinical trials targeting Aβ have failed to clearly demonstrate clinical benefit [14, 36] with the consequence that the amyloid hypothesis has been questioned [7, 40, 41].”
BackgroundSatlin, A., Wang, J., Logovinsky, V., Berry, S., Swanson, C., Dhadda, S., & Berry, D. A. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.01.001 · Cited by 89
Targeting microglia for the treatment of Alzheimer’s disease
McGeer, P. L., & McGeer, E. G. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.988707 · Cited by 88
Guercio, B. J., Donovan, N. J., Munro, C. E., Aghjayan, S. L., Wigman, S. E., Locascio, J. J., Amariglio, R. E., Rentz, D. M., Johnson, K. A., Sperling, R. A., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-150146 · Cited by 88
Immunotherapy in Parkinson’s Disease: Micromanaging Alpha-Synuclein Aggregation
George, S., & Brundin, P. (2015) · Journal of Parkinson's Disease · doi:10.3233/jpd-150630 · Cited by 86
Friend, Foe or Both? Immune Activity in Alzheimer’s Disease
Frost, G. R., Jonas, L. A., & Li, Y.-M. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00337 · Cited by 87
Drug development for Alzheimer’s disease: Review
Lao, K., Ji, N., Zhang, X., Qiao, W., Tang, Z., & Gou, X. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2018.1474361 · Cited by 86
“These findings, announced in 2012 and later published, showed that the drug failed to improve cognitive or functional outcomes [64].”
Background
Metadata
- Authors
- Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., & Mohs, R.
- Affiliations
- Baylor College of Medicine (US)
- University of California San Diego (US)
- Indiana University (US)
- The University of Tokyo (JP)
- Centre Hospitalier Universitaire de Toulouse (FR)
- University of Pennsylvania (US)
- University of Rochester Medicine (US)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-01-23
- Volume
- 370
- Issue
- 4
- Pages
- 311-321
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2015484447
- Cited by
- 1,668
- References
- 28
- Citations by year
- 2026: 63 · 2025: 84 · 2024: 110 · 2023: 116 · 2022: 101 · 2021: 103 · 2020: 154 · 2019: 145 · 2018: 155 · 2017: 163 · 2016: 183 · 2015: 178 · 2014: 111
- FWCI
- 140.73
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- solanezumab, Alzheimer's disease, amyloid-beta, anti-amyloid monoclonal antibodies, cognitive impairment, activities of daily living, mild to moderate Alzheimer's disease, placebo response
- MeSH terms
- Activities of Daily Living, Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Cognition, Double-Blind Method, Female, Humans, Male, Neuropsychological Tests, Severity of Illness Index, Biomarkers, Amyloid beta-Peptides, tau Proteins, Treatment Failure, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.